• Avaí Bio held a first joint steering committee meeting with Austrianova and Ospedale San Raffaele on its diabetes cell therapy program.
• Work will test encapsulation of San Raffaele stem cell-derived beta cells using Austrianova’s Cell-in-a-Box technology.
• Initial studies target beta-cell viability and function, setting the data threshold for any further development toward immune-protected transplantation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avai Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070845PRIMZONEFULLFEED9841211) on October 07, 2026, and is solely responsible for the information contained therein.